U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ACHIRAL
Molecular Formula C7H6O3
Molecular Weight 138.1207
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of Salicylic acid

SMILES

OC(=O)C1=C(O)C=CC=C1

InChI

InChIKey=YGSDEFSMJLZEOE-UHFFFAOYSA-N
InChI=1S/C7H6O3/c8-6-4-2-1-3-5(6)7(9)10/h1-4,8H,(H,9,10)

HIDE SMILES / InChI

Molecular Formula C7H6O3
Molecular Weight 138.1207
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: Description was created based on several sources, including https://www.drugs.com/pro/salicylic-acid.html

Methyl salicylate (or methyl 2-hydroxybenzoate), also known as wintergreen oil, is a natural product and is present in white wine, tea, porcini mushroom Boletus edulis, Bourbon vanilla, clary sage, red sage and fruits including cherry, apple, raspberry, papaya and plum. Methyl salicylate is topically used in combination with methanol and under brand name SALONPAS to temporarily relieves mild to moderate aches and pains of muscles and joints associated with: strains, sprains, simple backache, arthritis, bruises. The precise mechanism of action of methyl salicylate is not known, but there is suggested, that it cause dilation of the capillaries thereby increasing blood flow to the area.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
1.48 nM [Kd]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
SALONPAS

Approved Use

Temporarily relieves mild to moderate aches and pains of muscles and joints associated with: strains, sprains, simple backache, arthritis, bruises

Launch Date

2008
Palliative
SALONPAS

Approved Use

Temporarily relieves mild to moderate aches and pains of muscles and joints associated with: strains, sprains, simple backache, arthritis, bruises

Launch Date

2008
Palliative
SALONPAS

Approved Use

Temporarily relieves mild to moderate aches and pains of muscles and joints associated with: strains, sprains, simple backache, arthritis, bruises

Launch Date

2008
Palliative
SALONPAS

Approved Use

Temporarily relieves mild to moderate aches and pains of muscles and joints associated with: strains, sprains, simple backache, arthritis, bruises

Launch Date

2008
Primary
Salicylic Acid

Approved Use

Salicylic Acid 6% is a topical aid in the removal of excessive keratin in hyperkeratotic skin disorders including verrucae, and the various ichthyoses (vulgaris, sex-linked and lamellar), keratosis palmaris and plantaris keratosis pilaris, pityriasis rubra pilaris, and psoriasis (including body, scalp, palms and soles).

Launch Date

2012
Primary
Salicylic Acid

Approved Use

Salicylic Acid 6% is a topical aid in the removal of excessive keratin in hyperkeratotic skin disorders including verrucae, and the various ichthyoses (vulgaris, sex-linked and lamellar), keratosis palmaris and plantaris keratosis pilaris, pityriasis rubra pilaris, and psoriasis (including body, scalp, palms and soles).

Launch Date

2012
Primary
Salicylic Acid

Approved Use

Salicylic Acid 6% is a topical aid in the removal of excessive keratin in hyperkeratotic skin disorders including verrucae, and the various ichthyoses (vulgaris, sex-linked and lamellar), keratosis palmaris and plantaris keratosis pilaris, pityriasis rubra pilaris, and psoriasis (including body, scalp, palms and soles).

Launch Date

2012
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
238 min
500 mg single, intravenous
dose: 500 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
SALICYLIC ACID plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
30 % 1 times / 2 weeks multiple, topical
Dose: 30 %, 1 times / 2 weeks
Route: topical
Route: multiple
Dose: 30 %, 1 times / 2 weeks
Sources:
unhealthy, 23.05 ± 5.7 years
Health Status: unhealthy
Age Group: 23.05 ± 5.7 years
Sex: M+F
Sources:
Other AEs: Redness, Scales...
Other AEs:
Redness
Scales
Sources:
AEs

AEs

AESignificanceDosePopulation
Redness
30 % 1 times / 2 weeks multiple, topical
Dose: 30 %, 1 times / 2 weeks
Route: topical
Route: multiple
Dose: 30 %, 1 times / 2 weeks
Sources:
unhealthy, 23.05 ± 5.7 years
Health Status: unhealthy
Age Group: 23.05 ± 5.7 years
Sex: M+F
Sources:
Scales
30 % 1 times / 2 weeks multiple, topical
Dose: 30 %, 1 times / 2 weeks
Route: topical
Route: multiple
Dose: 30 %, 1 times / 2 weeks
Sources:
unhealthy, 23.05 ± 5.7 years
Health Status: unhealthy
Age Group: 23.05 ± 5.7 years
Sex: M+F
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG



Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
yes
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
likely
likely
major
no
no
no
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
PubMed

PubMed

TitleDatePubMed
False-high blood salicylate levels in neonates with hyperbilirubinemia.
2000 Dec
Directed control of electroosmotic flow in nonaqueous electrolytes using poly(ethylene glycol) coated capillaries.
2001
Risk of upper gastrointestinal bleeding and perforation associated with low-dose aspirin as plain and enteric-coated formulations.
2001
Nitric oxide: comparative synthesis and signaling in animal and plant cells.
2001 Apr
Sodium salicylate increases CYP2E1 levels and enhances arachidonic acid toxicity in HepG2 cells and cultured rat hepatocytes.
2001 Apr
Induction of wound response gene expression in tomato leaves by ionophores.
2001 Feb
Isolation and preliminary characterization of the medium-chain fatty acid:CoA ligase responsible for activation of short- and medium-chain fatty acids in colonic mucosa from swine.
2001 Feb
Acetylsalicylic acid and other salicylates in relation to Stevens-Johnson syndrome and toxic epidermal necrolysis.
2001 Feb
A novel pH-sensitive membrane from chitosan--TEOS IPN; preparation and its drug permeation characteristics.
2001 Feb
A hot pepper cDNA encoding a pathogenesis-related protein 4 is induced during the resistance response to tobacco mosaic virus.
2001 Feb 28
Molecular cloning of the nahG gene encoding salicylate hydroxylase from Pseudomonas fluorescens.
2001 Feb 28
Manipulation of salicylate content in Arabidopsis thaliana by the expression of an engineered bacterial salicylate synthase.
2001 Jan
Effect of 4-trifluoromethyl derivatives of salicylate on nuclear factor kappaB-dependent transcription in human astrocytoma cells.
2001 Jan
The possibility of achieving an interactive mixture with high dose homogeneity containing an extremely low proportion of a micronised drug.
2001 Jan
Induction of cell death in arabidopsis by superoxide in combination with salicylic acid or with protein synthesis inhibitors.
2001 Jan 1
Reversed-phase high-performance liquid chromatography versus spectrophotometric assay for thimerosal in Cuban recombinant hepatitis B vaccine.
2001 Jan 12
Salicylates inhibit T cell adhesion on endothelium under nonstatic conditions: induction of L-selectin shedding by a tyrosine kinase-dependent mechanism.
2001 Jan 15
Characterization of a rice (Oryza sativa L.) Bowman-Birk proteinase inhibitor: tightly light regulated induction in response to cut, jasmonic acid, ethylene and protein phosphatase 2A inhibitors.
2001 Jan 24
Selective suppression of CCAAT/enhancer-binding protein beta binding and cyclooxygenase-2 promoter activity by sodium salicylate in quiescent human fibroblasts.
2001 Jun 1
A recessive mutation in the Arabidopsis SSI2 gene confers SA- and NPR1-independent expression of PR genes and resistance against bacterial and oomycete pathogens.
2001 Mar
Signaling mediated by the closely related mammalian Rho family GTPases TC10 and Cdc42 suggests distinct functional pathways.
2001 Mar
The Arabidopsis downy mildew resistance gene, RPP13-Nd, functions independently of NDR1 and EDS1 and does not require the accumulation of salicylic acid.
2001 Mar
Effect of lipophilicity on in vivo iontophoretic delivery. I. NSAIDs.
2001 Mar
Identification of free radicals produced during phacoemulsification.
2001 Mar
Microdialysis of salicylic acid from viscous emulsion samples prior to high-performance liquid chromatographic determination.
2001 Mar 30
Determination of salicylate, gentisic acid and salicyluric acid in human urine by capillary electrophoresis with laser-induced fluorescence detection.
2001 Mar 5
Anti-inflammatory and antipyretic effects of Trigonella foenum-graecum leaves extract in the rat.
2001 May
Binding of cosalane--a novel highly lipophilic anti-HIV agent--to albumin and glycoprotein.
2001 May
In vitro dermal absorption of methyl salicylate, ethyl parathion, and malathion: first responder safety.
2007 Jun
Patents

Sample Use Guides

The preferable method of use is to apply Salicylic Acid 6% thoroughly to the affected area and to cover the treated area at night after washing and before retiring. Preferably, the skin should be hydrated for a least five minutes prior to application.
Route of Administration: Topical
In Vitro Use Guide
Salicylic acid inhibited hippuric acid formation in the homogenates obtained from the specimens of human liver with IC50 value 0.19 mM
Substance Class Chemical
Created
by admin
on Mon Mar 31 17:50:19 GMT 2025
Edited
by admin
on Mon Mar 31 17:50:19 GMT 2025
Record UNII
O414PZ4LPZ
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
Salicylic acid
EP   GREEN BOOK   HSDB   INCI   JAN   MART.   MI   USP   USP-RS   VANDF   WHO-DD   WHO-IP  
INCI  
Official Name English
SALICYLICUM ACIDUM
HPUS  
Preferred Name English
LAMIVUDINE IMPURITY C [EP IMPURITY]
Common Name English
SALICYLIC ACID [USP-RS]
Common Name English
2-HYDROXYBENZENECARBOXYLIC ACID
Systematic Name English
COMPOUND W
Brand Name English
SALICYLIC ACID [EP IMPURITY]
Common Name English
SALICYLIC ACID [USP]
Common Name English
SALICYLIC ACID [JAN]
Common Name English
SALICYLIC ACID [VANDF]
Common Name English
DR. SCHOLL'S CALLUS REMOVERS
Brand Name English
FEMA NO. 3985
Code English
SALICYLIC ACID [USP MONOGRAPH]
Common Name English
SALICYLIC ACID [MART.]
Common Name English
SULFASALAZINE IMPURITY H [EP IMPURITY]
Common Name English
SALICYLICUM ACIDUM [HPUS]
Common Name English
SALICYLIC ACID [GREEN BOOK]
Common Name English
SALICYLIC ACID [MI]
Common Name English
ACETYLSALICYLIC ACID IMPURITY C [EP IMPURITY]
Common Name English
SALICYLIC ACID [HSDB]
Common Name English
NSC-180
Code English
2-HYDROXYBENZOIC ACID [FHFI]
Common Name English
CARBASALATE CALCIUM IMPURITY C [EP IMPURITY]
Common Name English
Salicylic acid [WHO-DD]
Common Name English
DL-LYSINE ACETYLSALICYLATE IMPURITY A [EP IMPURITY]
Common Name English
2-HYDROXYBENZOIC ACID
FHFI  
Systematic Name English
ACIDUM SALICYLICUM [WHO-IP LATIN]
Common Name English
SALICYLIC ACID [EP MONOGRAPH]
Common Name English
SALICYLIC ACID [WHO-IP]
Common Name English
K-557
Code English
MESALAZINE IMPURITY H [EP IMPURITY]
Common Name English
Classification Tree Code System Code
CFR 21 CFR 358.710
Created by admin on Mon Mar 31 17:50:19 GMT 2025 , Edited by admin on Mon Mar 31 17:50:19 GMT 2025
CFR 21 CFR 333.310
Created by admin on Mon Mar 31 17:50:19 GMT 2025 , Edited by admin on Mon Mar 31 17:50:19 GMT 2025
NCI_THESAURUS C257
Created by admin on Mon Mar 31 17:50:19 GMT 2025 , Edited by admin on Mon Mar 31 17:50:19 GMT 2025
NCI_THESAURUS C52588
Created by admin on Mon Mar 31 17:50:19 GMT 2025 , Edited by admin on Mon Mar 31 17:50:19 GMT 2025
CFR 21 CFR 358.510
Created by admin on Mon Mar 31 17:50:19 GMT 2025 , Edited by admin on Mon Mar 31 17:50:19 GMT 2025
WHO-VATC QD01AE12
Created by admin on Mon Mar 31 17:50:19 GMT 2025 , Edited by admin on Mon Mar 31 17:50:19 GMT 2025
CFR 21 CFR 862.3830
Created by admin on Mon Mar 31 17:50:19 GMT 2025 , Edited by admin on Mon Mar 31 17:50:19 GMT 2025
EPA PESTICIDE CODE 76602
Created by admin on Mon Mar 31 17:50:19 GMT 2025 , Edited by admin on Mon Mar 31 17:50:19 GMT 2025
CFR 21 CFR 358.720
Created by admin on Mon Mar 31 17:50:19 GMT 2025 , Edited by admin on Mon Mar 31 17:50:19 GMT 2025
WHO-VATC QS01BC08
Created by admin on Mon Mar 31 17:50:19 GMT 2025 , Edited by admin on Mon Mar 31 17:50:19 GMT 2025
WHO-ATC S01BC08
Created by admin on Mon Mar 31 17:50:19 GMT 2025 , Edited by admin on Mon Mar 31 17:50:19 GMT 2025
CFR 21 CFR 358.110
Created by admin on Mon Mar 31 17:50:19 GMT 2025 , Edited by admin on Mon Mar 31 17:50:19 GMT 2025
FDA ORPHAN DRUG 359211
Created by admin on Mon Mar 31 17:50:19 GMT 2025 , Edited by admin on Mon Mar 31 17:50:19 GMT 2025
WHO-VATC QM02AC99
Created by admin on Mon Mar 31 17:50:19 GMT 2025 , Edited by admin on Mon Mar 31 17:50:19 GMT 2025
JECFA EVALUATION 2-HYDROXYBENZOIC ACID
Created by admin on Mon Mar 31 17:50:19 GMT 2025 , Edited by admin on Mon Mar 31 17:50:19 GMT 2025
WHO-ATC D01AE12
Created by admin on Mon Mar 31 17:50:19 GMT 2025 , Edited by admin on Mon Mar 31 17:50:19 GMT 2025
WHO-ESSENTIAL MEDICINES LIST 13.4
Created by admin on Mon Mar 31 17:50:19 GMT 2025 , Edited by admin on Mon Mar 31 17:50:19 GMT 2025
Code System Code Type Description
RXCUI
9525
Created by admin on Mon Mar 31 17:50:19 GMT 2025 , Edited by admin on Mon Mar 31 17:50:19 GMT 2025
PRIMARY
JECFA MONOGRAPH
891
Created by admin on Mon Mar 31 17:50:19 GMT 2025 , Edited by admin on Mon Mar 31 17:50:19 GMT 2025
PRIMARY
HSDB
672
Created by admin on Mon Mar 31 17:50:19 GMT 2025 , Edited by admin on Mon Mar 31 17:50:19 GMT 2025
PRIMARY
FDA UNII
O414PZ4LPZ
Created by admin on Mon Mar 31 17:50:19 GMT 2025 , Edited by admin on Mon Mar 31 17:50:19 GMT 2025
PRIMARY
PUBCHEM
338
Created by admin on Mon Mar 31 17:50:19 GMT 2025 , Edited by admin on Mon Mar 31 17:50:19 GMT 2025
PRIMARY
RXCUI
9522
Created by admin on Mon Mar 31 17:50:19 GMT 2025 , Edited by admin on Mon Mar 31 17:50:19 GMT 2025
ALTERNATIVE
RS_ITEM_NUM
1609002
Created by admin on Mon Mar 31 17:50:19 GMT 2025 , Edited by admin on Mon Mar 31 17:50:19 GMT 2025
PRIMARY
LACTMED
Salicylic Acid
Created by admin on Mon Mar 31 17:50:19 GMT 2025 , Edited by admin on Mon Mar 31 17:50:19 GMT 2025
PRIMARY
EVMPD
SUB15180MIG
Created by admin on Mon Mar 31 17:50:19 GMT 2025 , Edited by admin on Mon Mar 31 17:50:19 GMT 2025
PRIMARY
WIKIPEDIA
SALICYLIC ACID
Created by admin on Mon Mar 31 17:50:19 GMT 2025 , Edited by admin on Mon Mar 31 17:50:19 GMT 2025
PRIMARY
CAS
69-72-7
Created by admin on Mon Mar 31 17:50:19 GMT 2025 , Edited by admin on Mon Mar 31 17:50:19 GMT 2025
PRIMARY
WIKIPEDIA
Medical uses of salicylic acid
Created by admin on Mon Mar 31 17:50:19 GMT 2025 , Edited by admin on Mon Mar 31 17:50:19 GMT 2025
PRIMARY
ECHA (EC/EINECS)
200-712-3
Created by admin on Mon Mar 31 17:50:19 GMT 2025 , Edited by admin on Mon Mar 31 17:50:19 GMT 2025
PRIMARY
MESH
D020156
Created by admin on Mon Mar 31 17:50:19 GMT 2025 , Edited by admin on Mon Mar 31 17:50:19 GMT 2025
PRIMARY
CHEBI
30762
Created by admin on Mon Mar 31 17:50:19 GMT 2025 , Edited by admin on Mon Mar 31 17:50:19 GMT 2025
PRIMARY
IUPHAR
4306
Created by admin on Mon Mar 31 17:50:19 GMT 2025 , Edited by admin on Mon Mar 31 17:50:19 GMT 2025
PRIMARY
NSC
180
Created by admin on Mon Mar 31 17:50:19 GMT 2025 , Edited by admin on Mon Mar 31 17:50:19 GMT 2025
PRIMARY
SMS_ID
100000090038
Created by admin on Mon Mar 31 17:50:19 GMT 2025 , Edited by admin on Mon Mar 31 17:50:19 GMT 2025
PRIMARY
DRUG CENTRAL
2416
Created by admin on Mon Mar 31 17:50:19 GMT 2025 , Edited by admin on Mon Mar 31 17:50:19 GMT 2025
PRIMARY
CHEBI
16914
Created by admin on Mon Mar 31 17:50:19 GMT 2025 , Edited by admin on Mon Mar 31 17:50:19 GMT 2025
PRIMARY
DAILYMED
O414PZ4LPZ
Created by admin on Mon Mar 31 17:50:19 GMT 2025 , Edited by admin on Mon Mar 31 17:50:19 GMT 2025
PRIMARY
MERCK INDEX
m9739
Created by admin on Mon Mar 31 17:50:19 GMT 2025 , Edited by admin on Mon Mar 31 17:50:19 GMT 2025
PRIMARY Merck Index
NCI_THESAURUS
C61934
Created by admin on Mon Mar 31 17:50:19 GMT 2025 , Edited by admin on Mon Mar 31 17:50:19 GMT 2025
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
SALICYLIC ACID
Created by admin on Mon Mar 31 17:50:19 GMT 2025 , Edited by admin on Mon Mar 31 17:50:19 GMT 2025
PRIMARY Description: Colourless crystals, usually needle-like, or a white, crystalline powder; odourless. Solubility: Slightly soluble in water; soluble in 4 parts of ethanol (~750 g/l) TS and in 3 parts of ether R. Category: Keratolytic. Storage: Salicylic acid should be kept in a well-closed container. Definition: Salicylic acid contains not less than 99.0% and not more than 101.0% of C7H6O3, calculated with reference to the dried substance.
ChEMBL
CHEMBL424
Created by admin on Mon Mar 31 17:50:19 GMT 2025 , Edited by admin on Mon Mar 31 17:50:19 GMT 2025
PRIMARY
DRUG BANK
DB00936
Created by admin on Mon Mar 31 17:50:19 GMT 2025 , Edited by admin on Mon Mar 31 17:50:19 GMT 2025
PRIMARY
EPA CompTox
DTXSID7026368
Created by admin on Mon Mar 31 17:50:19 GMT 2025 , Edited by admin on Mon Mar 31 17:50:19 GMT 2025
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
PARENT -> CONSTITUENT ALWAYS PRESENT
Salicylic acid content for water extract of plant callus was 3.22+/-0.06 as expressed as mg/100 g of dry base of extract. For the analysis of phenolic acids, a Nova pack C18 UG120 equipped with a Guard column, a JASCO HPLC system consisting of a column oven, a UV-Vis diode array detector set at 280 nm, a Liquid chromatography pump and a ChromNAV software program were used.
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
PARENT -> CONSTITUENT ALWAYS PRESENT
PARENT -> CONSTITUENT ALWAYS PRESENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
TRANSPORTER -> INHIBITOR
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
DERIVATIVE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
PARENT -> CONSTITUENT ALWAYS PRESENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
Related Record Type Details
PARENT -> METABOLITE ACTIVE
PRODRUG -> METABOLITE ACTIVE
Related Record Type Details
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
EP
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
Ph.Eur.; USP
IMPURITY -> PARENT
INTERNATIONAL PHARMACOPEIA
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
INTERNATIONAL PHARMACOPEIA
IMPURITY -> PARENT
USP
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
USP
PARENT -> IMPURITY
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
PARENT -> IMPURITY
Correction factors: for the calculation of contents, multiply the peak areas by 1.4
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
PARENT -> IMPURITY
Related Record Type Details
ACTIVE MOIETY